TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Short Interest Update

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) was the recipient of a significant drop in short interest in June. As of June 15th, there was short interest totalling 24,900 shares, a drop of 56.6% from the May 31st total of 57,400 shares. Based on an average daily volume of 2,310,000 shares, the short-interest ratio is currently 0.0 days.

TC Biopharm Trading Down 0.7 %

Shares of NASDAQ TCBP traded down $0.01 during midday trading on Friday, reaching $0.82. 106,252 shares of the company’s stock traded hands, compared to its average volume of 143,803. The company has a debt-to-equity ratio of 1.31, a current ratio of 0.88 and a quick ratio of 0.88. The stock’s 50 day simple moving average is $1.15 and its 200-day simple moving average is $1.54. TC Biopharm has a one year low of $0.72 and a one year high of $19.60.

TC Biopharm (NASDAQ:TCBP) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($2.80) earnings per share (EPS) for the quarter.

TC Biopharm Company Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.